Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
79.10
-0.10 (-0.13%)
Apr 2, 2025, 1:30 PM CST
-19.27%
Market Cap 12.12B
Revenue (ttm) 418.69M
Net Income (ttm) -1.08B
Shares Out 154.78M
EPS (ttm) -7.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,812
Average Volume 225,719
Open 79.20
Previous Close 79.10
Day's Range 78.00 - 79.20
52-Week Range 68.40 - 101.00
Beta 1.21
RSI 23.19
Earnings Date May 12, 2025

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline... [Read more]

Sector Healthcare
Founded 2013
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6576
Full Company Profile

Financial Performance

In 2024, Foresee Pharmaceuticals's revenue was 418.69 million, an increase of 114.67% compared to the previous year's 195.04 million. Losses were -1.08 billion, 4.32% more than in 2023.

Financial Statements

News

There is no news available yet.